Skip to main content
Erschienen in: Tumor Biology 3/2013

01.06.2013 | Research Article

Discussion of modifying stage IV gastric cancer based on Borrmann classification

verfasst von: Bin Yang, Guoqiang Wu, Xiaochen Wang, Xuefeng Zhang

Erschienen in: Tumor Biology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

This study aims to investigate the prognostic significance of reclassification of stage IV gastric cancers in conjunction with Borrmann type. A total of 1,673 gastric cancer patients who received a gastrectomy between 1980 and 2003 were retrospectively evaluated. Of the patients, 244 (14.58 %), 344 (20.56 %), 589 (35.21 %), and 496 (29.65 %) had stage I, II, III, and IV cancers, respectively. After Cox regression analysis, Borrmann type was identified to be the independent prognostic factor in stage IV gastric cancer. The disease-specific postoperative survival of patients with Borrmann I, II, and III tumors was clearly distinguished by TNM classification system (P < 0.05), while it failed to classify Borrmann IV tumors (P = 0.147). Interestingly, the disease-specific postoperative survival of stage IV patients with Borrmann IV tumors (group 1) was significantly poor than the cases with stage IV but not Borrmann IV tumors (group 2), as well as the patients with Borrmann IV while not included in stage IV tumors (group 3) (P = 0.022 and P = 0.000, respectively). Meanwhile, the disease-specific postoperative survival was not observed as significantly different between group 2 and group 3 (P = 0.063); furthermore, group 2 + 3 had a better prognosis than group 1 (introduced stage IVa vs. stage IVb; P = 0.006). Reclassification of stage IV through combining the present TNM classification system with Borrmann type may more accurately predict the prognosis of patients.
Literatur
1.
Zurück zum Zitat Shimoyama S, Seto Y, Yasuda H, Mafune K, Kaminishi M. Concepts, rationale, and current outcomes of less invasive surgical strategies for early gastric cancer: date from a quarter-century of experience in a single institution. World J Surg. 2005;29:58–65.PubMedCrossRef Shimoyama S, Seto Y, Yasuda H, Mafune K, Kaminishi M. Concepts, rationale, and current outcomes of less invasive surgical strategies for early gastric cancer: date from a quarter-century of experience in a single institution. World J Surg. 2005;29:58–65.PubMedCrossRef
2.
Zurück zum Zitat Lindsey H. Preoperative chemoradiotherapy shows promise in gastric cancer. Lancet Oncol. 2004;5:519.PubMedCrossRef Lindsey H. Preoperative chemoradiotherapy shows promise in gastric cancer. Lancet Oncol. 2004;5:519.PubMedCrossRef
3.
Zurück zum Zitat Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27(6):851–6.PubMedCrossRef Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27(6):851–6.PubMedCrossRef
4.
Zurück zum Zitat Ohtsu A, Yoshida S, Sajio N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 2006;24:2188–96.PubMedCrossRef Ohtsu A, Yoshida S, Sajio N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 2006;24:2188–96.PubMedCrossRef
5.
Zurück zum Zitat Adchi Y, Shiraishi N, Kitano S. Modern treatment of early gastric cancer: review of the Japanese experience. Dig Surg. 2002;19:333–9.CrossRef Adchi Y, Shiraishi N, Kitano S. Modern treatment of early gastric cancer: review of the Japanese experience. Dig Surg. 2002;19:333–9.CrossRef
6.
Zurück zum Zitat Schwartz GK, Winter K, Minsky BD, Crane C, Thomson PJ, Anne P, et al. Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114). J Clin Oncol. 2009;27(12):1956–62.PubMedCrossRef Schwartz GK, Winter K, Minsky BD, Crane C, Thomson PJ, Anne P, et al. Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114). J Clin Oncol. 2009;27(12):1956–62.PubMedCrossRef
7.
Zurück zum Zitat Küchler T, Bestmann B, Rappat S, Henne-Bruns D, Wood-Dauphinee S. Impact of psychotherapeutic support for patients with gastrointestinal cancer undergoing surgery: 10-year survival results of a randomized trial. J Clin Oncol. 2007;25(19):2702–8.PubMedCrossRef Küchler T, Bestmann B, Rappat S, Henne-Bruns D, Wood-Dauphinee S. Impact of psychotherapeutic support for patients with gastrointestinal cancer undergoing surgery: 10-year survival results of a randomized trial. J Clin Oncol. 2007;25(19):2702–8.PubMedCrossRef
8.
Zurück zum Zitat Yamashita K, Sakuramoto S, Kikuchi S, Katada N, Kobayashi N, Watanabe M. Validation of staging systems for gastric cancer. Gastric Cancer. 2008;11(2):111–8.PubMedCrossRef Yamashita K, Sakuramoto S, Kikuchi S, Katada N, Kobayashi N, Watanabe M. Validation of staging systems for gastric cancer. Gastric Cancer. 2008;11(2):111–8.PubMedCrossRef
9.
Zurück zum Zitat Hidaka H, Eto T, Maehara N, Jimi S, Hotokezaka M, Chijiiwa K. Comparative effect of lymph node metastasis classified by the anatomical site or by the number of nodes involved on prognosis of patients with gastric cancer. Hepatogastroenterology. 2008;55(88):2269–72.PubMed Hidaka H, Eto T, Maehara N, Jimi S, Hotokezaka M, Chijiiwa K. Comparative effect of lymph node metastasis classified by the anatomical site or by the number of nodes involved on prognosis of patients with gastric cancer. Hepatogastroenterology. 2008;55(88):2269–72.PubMed
10.
Zurück zum Zitat Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol. 2005;23(28):7114–24.PubMedCrossRef Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol. 2005;23(28):7114–24.PubMedCrossRef
11.
Zurück zum Zitat Tiberio GA, Coniglio A, Marchet A, Marrelli D, Giacopuzzi S, Baiocchi L, et al. Metachronous hepatic metastases from gastric carcinoma: a multicentric survey. Eur J Surg Oncol. 2009;35(5):486–91.PubMedCrossRef Tiberio GA, Coniglio A, Marchet A, Marrelli D, Giacopuzzi S, Baiocchi L, et al. Metachronous hepatic metastases from gastric carcinoma: a multicentric survey. Eur J Surg Oncol. 2009;35(5):486–91.PubMedCrossRef
12.
Zurück zum Zitat Huang B, Zheng X, Wang Z, Wang M, Dong Y, Zhao B, et al. Prognostic significance of the number of metastatic lymph nodes: is UICC/TNM node classification perfectly suitable for early gastric cancer? Ann Surg Oncol. 2009;16(1):61–7.PubMedCrossRef Huang B, Zheng X, Wang Z, Wang M, Dong Y, Zhao B, et al. Prognostic significance of the number of metastatic lymph nodes: is UICC/TNM node classification perfectly suitable for early gastric cancer? Ann Surg Oncol. 2009;16(1):61–7.PubMedCrossRef
13.
Zurück zum Zitat Nitti D, Marchet A, Mocellin S, Rossi GM, Ambrosi A, Mencarelli R. Prognostic value of subclassification of T2 tumours in patients with gastric cancer. Br J Surg. 2009;96(4):398–404.PubMedCrossRef Nitti D, Marchet A, Mocellin S, Rossi GM, Ambrosi A, Mencarelli R. Prognostic value of subclassification of T2 tumours in patients with gastric cancer. Br J Surg. 2009;96(4):398–404.PubMedCrossRef
14.
Zurück zum Zitat Sun Z, Zhu GL, Lu C, Guo PT, Huang BJ, Li K, et al. A novel subclassification of pT2 gastric cancers according to the depth of muscularis propria invasion: superficial muscularis propria versus deep muscularis propria/subserosa. Ann Surg. 2009;249(5):768–75.PubMedCrossRef Sun Z, Zhu GL, Lu C, Guo PT, Huang BJ, Li K, et al. A novel subclassification of pT2 gastric cancers according to the depth of muscularis propria invasion: superficial muscularis propria versus deep muscularis propria/subserosa. Ann Surg. 2009;249(5):768–75.PubMedCrossRef
15.
Zurück zum Zitat Kim DH, Oh CA, Oh SJ, Choi MG, Noh JH, Sohn TS, et al. Validation of seventh edition AJCC gastric cancer staging modifications. J Surg Oncol. 2012;105(1):26–30.PubMedCrossRef Kim DH, Oh CA, Oh SJ, Choi MG, Noh JH, Sohn TS, et al. Validation of seventh edition AJCC gastric cancer staging modifications. J Surg Oncol. 2012;105(1):26–30.PubMedCrossRef
16.
Zurück zum Zitat Chen CY, Wu CW, Lo SS, Hsieh MC, Lui WY, Shen KH. Peritoneal carcinomatosis and lymph node metastasis are prognostic indicators in patients with Borrmann type IV gastric carcinoma. Hepatogastroenterology. 2002;49(45):874–7.PubMed Chen CY, Wu CW, Lo SS, Hsieh MC, Lui WY, Shen KH. Peritoneal carcinomatosis and lymph node metastasis are prognostic indicators in patients with Borrmann type IV gastric carcinoma. Hepatogastroenterology. 2002;49(45):874–7.PubMed
17.
Zurück zum Zitat Kim DY, Kim HR, Kim YJ, Kim S. Clinicopathological features of patients with Borrmann type IV gastric carcinoma. ANZ J Surg. 2002;72(10):739–42.PubMedCrossRef Kim DY, Kim HR, Kim YJ, Kim S. Clinicopathological features of patients with Borrmann type IV gastric carcinoma. ANZ J Surg. 2002;72(10):739–42.PubMedCrossRef
18.
Zurück zum Zitat An JY, Kang TH, Choi MG, Noh JH, Sohn TS, et al. Borrmann type IV: an independent prognostic factor for survival in gastric cancer. J Gastrointest Surg. 2008;12(8):1364–9.PubMedCrossRef An JY, Kang TH, Choi MG, Noh JH, Sohn TS, et al. Borrmann type IV: an independent prognostic factor for survival in gastric cancer. J Gastrointest Surg. 2008;12(8):1364–9.PubMedCrossRef
19.
Zurück zum Zitat International Union Against Cancer. In: Sobin LH, Wittekind CH, editors. TNM classification of malignant tumors. 5th ed. New York: Wiley; 1997. International Union Against Cancer. In: Sobin LH, Wittekind CH, editors. TNM classification of malignant tumors. 5th ed. New York: Wiley; 1997.
20.
Zurück zum Zitat Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 2nd English edition. Gastric Cancer. 1998;1:10–24.PubMedCrossRef Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 2nd English edition. Gastric Cancer. 1998;1:10–24.PubMedCrossRef
21.
Zurück zum Zitat Teramoto K, Tada M, Tamoto E, Abe M, Kawakami A, Komuro K, et al. Prediction of lymphatic invasion/lymph node metastasis, recurrence, and survival in patients with gastric cancer by cDNA array-based expression profiling. J Surg Res. 2005;124:225–36.PubMedCrossRef Teramoto K, Tada M, Tamoto E, Abe M, Kawakami A, Komuro K, et al. Prediction of lymphatic invasion/lymph node metastasis, recurrence, and survival in patients with gastric cancer by cDNA array-based expression profiling. J Surg Res. 2005;124:225–36.PubMedCrossRef
22.
Zurück zum Zitat Rabin I, Chikman B, Lavy R, Sandbank J, Maklakovsky M, Gold-Deutch R, et al. Gastrointestinal stromal tumors: a 19 year experience. Isr Med Assoc J. 2009;11(2):98–102.PubMed Rabin I, Chikman B, Lavy R, Sandbank J, Maklakovsky M, Gold-Deutch R, et al. Gastrointestinal stromal tumors: a 19 year experience. Isr Med Assoc J. 2009;11(2):98–102.PubMed
23.
Zurück zum Zitat An JY, Ha TK, Noh JH, Sohn TS, Kim S. Proposal to subclassify stage IV gastric cancer into IVA, IVB, and IVM. Arch Surg. 2009;144(1):38–45. discussion 45.PubMedCrossRef An JY, Ha TK, Noh JH, Sohn TS, Kim S. Proposal to subclassify stage IV gastric cancer into IVA, IVB, and IVM. Arch Surg. 2009;144(1):38–45. discussion 45.PubMedCrossRef
24.
Zurück zum Zitat Li C, Yan M, Chen J, Xiang M, Zhu ZG, Lin YZ. Prognostic influence of sub-stages according to pTNM categories in patients with stage IV gastric cancer. J Surg Oncol. 2009;99(6):324–8.PubMedCrossRef Li C, Yan M, Chen J, Xiang M, Zhu ZG, Lin YZ. Prognostic influence of sub-stages according to pTNM categories in patients with stage IV gastric cancer. J Surg Oncol. 2009;99(6):324–8.PubMedCrossRef
Metadaten
Titel
Discussion of modifying stage IV gastric cancer based on Borrmann classification
verfasst von
Bin Yang
Guoqiang Wu
Xiaochen Wang
Xuefeng Zhang
Publikationsdatum
01.06.2013
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 3/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0673-7

Weitere Artikel der Ausgabe 3/2013

Tumor Biology 3/2013 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.